Drug intelligence / Profile preview

sintilimab + linperlisib

Development stage: Unknown
Lead developer: Innovent Biologics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

This combination involves **sintilimab**, a recombinant fully human anti-programmed death 1 (PD-1) monoclonal antibody, and **linperlisib**, a phosphoinositide 3-kinase delta (PI3Kδ) inhibitor. Sintilimab blocks the interaction between PD-1 and its ligand, enhancing immune responses against cancer cells. Linperlisib targets the PI3Kδ pathway, which is crucial for tumor survival and progression. The combination is being studied for its potential in treating various cancers, including relapsed or refractory blood cancers.

Targets

PDCD1 (Programmed cell death protein 1 receptor)PIK3CD (Phosphatidylinositol 3-kinase delta)

Beyond the preview

Go deeper on sintilimab + linperlisib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sintilimab + linperlisib.

Explore the full profile